- Report
- February 2024
- 70 Pages
Indonesia
From €4252EUR$4,750USD£3,622GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4252EUR$4,750USD£3,622GBP
- Report
- February 2024
- 70 Pages
India
From €4252EUR$4,750USD£3,622GBP
- Report
- August 2023
- 150 Pages
North America
From €4252EUR$4,750USD£3,622GBP
- Report
- August 2023
- 70 Pages
Africa, Middle East
From €4252EUR$4,750USD£3,622GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4252EUR$4,750USD£3,622GBP
- Report
- August 2023
- 70 Pages
Latin America
From €4252EUR$4,750USD£3,622GBP
- Report
- October 2022
- 70 Pages
Africa
From €4252EUR$4,750USD£3,622GBP
- Report
- August 2020
- 150 Pages
Global
From €3805EUR$4,250USD£3,241GBP
- Report
- May 2024
- 213 Pages
Global
From €4472EUR$4,995USD£3,809GBP
- Drug Pipelines
- February 2018
- 33 Pages
Global
From €8952EUR$10,000USD£7,625GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €448EUR$500USD£381GBP
Invokana is a prescription medication used to treat type 2 diabetes, a chronic endocrine and metabolic disorder. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose by the kidneys, allowing it to be eliminated in the urine. Invokana is taken orally once a day and is typically used in combination with diet and exercise to improve glycemic control. It is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Invokana is marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Other companies in the market include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi. Show Less Read more
